logo
  

Avadel : FDA's Review Of NDA Of FT218 On Narcolepsy Still Ongoing, No Action Taken In October

The U.S. Food and Drug Administration notified Avadel Pharmaceuticals plc (AVDL) that the review of the New Drug Application (NDA) for FT218 is still ongoing, and action will likely not be taken in October.

AVDL closed Friday regular trading at $9.99 up $0.65 or 6.96%. But in the after-hours trade, the stock dropped $1.43 or 14.31%.

The FDA informed the company that there are no information requests at this time and a new target action date will be provided as soon as possible.

The company said it has not been informed of any deficiencies in its application and remain fully committed to work closely with the FDA for the duration of its review of our NDA for FT218.

FT218 is an investigational formulation of sodium oxybate leveraging Avadel's proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

In February 2021, the FDA accepted Avadel's NDA for FT218 and assigned a target action date of October 15, 2021. The NDA submission is supported by positive data from the pivotal Phase 3 REST-ON study, which was completed under a Special Protocol Assessment (SPA) agreement with the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
RELATED NEWS
Follow RTT